• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

York Instruments Acquires Elekta’s MEG business

Share:

July 29, 2018

MEG is a diagnostic functional neuroimaging technique for mapping brain activity.

York Instruments, a subsidiary of Croton Healthcare, LLC announced today that it has completed the acquisition of Elekta’s Magnetoencephalography business.

MEG is a diagnostic functional neuroimaging technique for mapping brain activity. This can be applied in a clinical setting to find locations of abnormalities as well as in a research setting to simply measure brain activity. Elekta’s MEG business, known as MEGIN, is a leading supplier of magnetoencephalography technology, with more than 100 delivered MEG systems worldwide.

Elekta’s head of portfolio and chief strategy officer, Maurits Wolleswinkel, commented, “Elekta has successfully developed the MEG business over the past decade, but recently took the strategic decision that it is no longer a part of our core treatment solutions and oncology informatics business. Consequently, we have been looking to divest MEGIN and are really pleased to have found a new home for it and its team at York Instruments. York Instruments is committed to continue supporting all MEG customers while further advancing the science and clinical adoption of MEG. Nevertheless, Elekta will continue to be engaged in sales and support in the short term to ensure a smooth transition.”

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

Janne Huhtala, head of Elekta’s global MEG business, said, “This move supports not only the important future development of MEG technology, but also the customers of Elekta and York Instruments, as we bring our deep knowledge and years of experience to the company.”

Gordon Baltzer, CEO of York Instruments, added, “The combination of Elekta’s experience and York Instruments’ advanced technology provides an exciting new future for MEG. We look forward to serving Elekta’s current customers and expanding the MEG market beyond its current borders.”

The divestment is expected to be closed during the first quarter of Elekta’s fiscal year 2018/19. Elekta’s MEGIN business had net sales of about SEK 102M (Approx. $11M U.S.) in the fiscal year 2017/18. No material affect is expected on Elekta’s operating results of the first quarter of fiscal year 2018/19. Further financial details of the transaction were not disclosed.

Date: July 30, 2018

Source: MPO

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • CODA Biotherapeutics Announces Series A Extension, Bringing Total Round to $34 MillionCODA Biotherapeutics Announces Series A Extension, Bringing Total Round to $34 Million
  • Netflix Documentary Exposes the Dangers of the Medical Device IndustryNetflix Documentary Exposes the Dangers of the Medical Device Industry
  • SynsorMed, Charles Barkley Foundation Partner to Combat Health Disparities for Black Americans Impacted by COVID-19SynsorMed, Charles Barkley Foundation Partner to Combat Health Disparities for Black Americans Impacted by COVID-19
  • ABM Respiratory Care Announces the FDA Clearance of the BiWaze Clear SystemABM Respiratory Care Announces the FDA Clearance of the BiWaze Clear System
  • Biofourmis’ Biovitals™ Analytics Engine Receives FDA Clearance for Ambulatory Physiologic MonitoringBiofourmis’ Biovitals™ Analytics Engine Receives FDA Clearance for Ambulatory Physiologic Monitoring
  • Akebia Therapeutics Files Definitive Proxy Statement in Connection with Proposed Merger with Keryx BiopharmaceuticalsAkebia Therapeutics Files Definitive Proxy Statement in Connection with Proposed Merger with Keryx Biopharmaceuticals
  • Marshfield Clinic Health System to Launch Rural Health Equity InitiativeMarshfield Clinic Health System to Launch Rural Health Equity Initiative
  • To Build a More Equitable Health System, Experts say Start with Tech Insights

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications